The Total Synthesis of Natural Products: Acyclic and Monocyclic Sesquiterpenes

By Michael C. Pirrung, Andrew T. Morehead, Jr. and David Goldsmith

The indispensable reference for the twenty-first century chemist...

A fascinating and comprehensive look into one of chemistry's fastest growing specialties--sesquiterpene synthesis--Volume Ten of The Total Synthesis of Natural Products focuses on acyclic and monocyclic compounds and sheds light on the structure and makeup of this important class of hydrocarbons.

A useful and practical tool for researchers interested in locating any of the major classes of sesquiterpene compounds, the author will also provide, if needed, a database to the more than 1,600 articles on sesquiterpene synthesis. The ultimate index to the newest experimental work in synthetic chemistry, this latest volume in The Total Synthesis of Natural Products series is also a glossary to the new language of chemistry in the next century.

Look for the following related title in the series:

THE TOTAL SYNTHESIS OF NATURAL PRODUCTS, Volume Eleven

Volume Eleven continues the authoritative coverage on sesquiterpene synthesis begun in Volume Ten, examining compounds with bicyclic and tricyclic ring structures., 1997 (0-471-18874-3)

The research on the synthesis of sesquiterpenes, derivatives of terpenes, a class of hydrocarbons commonly found in oils, resins, and balsams, has grown exponentially over the past fifteen years. With over 500 sesquiterpene syntheses already developed, the literature on this experimental specialty is voluminous, now encompassing over 1,600 re-search papers. Volume Ten in The Total Synthesis of Natural Products provides a systematic and comprehensive look at acyclic and monocyclic compounds in sesquiterpene synthesis.

Reflecting one of the significant changes in sesquiterpene re-search, that is, the increase in compound targets prepared in an optically active form, the present volume includes their absolute configurations, signs of optical rotation, or both.

This newest volume in The Total Synthesis of Natural Products series is an "A-to-Z" look at acyclic and monocyclic compounds in sesquiterpene synthesis, one of the most dynamic areas in the ongoing revolution in chemical synthesis, and is a must for the chemical professional.

• Language: English
• Publisher: Wiley-Interscience
• Release date: Sep 22, 2009
• ISBN: 9780470129623

Michael C. Pirrung

Michael Pirrung, Ph.D., was trained as a synthetic organic chemist at UT-Austin, UC-Berkeley, and Columbia University with eminent synthetic chemists Clayton Heathcock and Gilbert Stork. His independent career began in the 1980s at Stanford University and the biotech start-up company Affymax. In 1990, he joined Duke University where he founded and directed the Program in Biological Chemistry. In 2004, he joined the UC-Riverside Chemistry department as UC Presidential Chair, and in 2012 became Distinguished Professor. He has been a visiting professor at UC-Berkeley, Baylor College of Medicine, Oxford, UC-San Diego, UC-Irvine, and Caltech. He has trained over 100 graduate students and postdoctoral fellows. He has held Hertz, Sloan, and Guggenheim fellowships and a NSF Presidential Young Investigator Award. He has over 170 peer-reviewed publications, more than 40 US and international patents, and has authored six books. The scope of his research has been broad, including natural product total synthesis, photochemical methods development, mechanistic enzymology, rhodium carbenoid chemistry, microarrays, combinatorial chemistry, and medicinal chemistry. His current work emphasizes peptide chemistry. His microarray work has been particularly recognized, with the 1991 AAAS-Newcomb Cleveland Prize, the 1993 Intellectual Property Owners Distinguished Inventor Award, the 2004 Chemical Pioneer Award of the American Institute of Chemists, and the 2006 European Inventor of the Year (for small and medium-sized enterprises). His editorial board service includes Cell Chemical Biology and Journal of Combinatorial Chemistry. He has worked extensively with development-stage and Fortune 500 companies as a consultant or scientific advisory board member. He also has an active practice as an expert witness for litigation in nucleic acid diagnostics and generic drugs.

Book preview